Inventor · disambiguated record
Maria Jure-Kunkel
Also filed as: JURE-KUNKEL MARIA · JURE-KUNKEL MARIA N
37 granted patents·33 pending applications·1,388 citations·filing 2004–2025
98Inventor score
Top patents by PatentIndex Score
70 records- 0198US10604575B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 31, 2020·26 cites·17 claims
- 0298US10323092B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 18, 2019·30 cites·26 claims
- 0398US10323093B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 18, 2019·29 cites·18 claims
- 0498US10316091B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 11, 2019·30 cites·26 claims
- 0598US10308714B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 4, 2019·30 cites·27 claims
- 0698US10266595B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·28 cites·30 claims
- 0798US10266594B1Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·29 cites·30 claims
- 0898US10266596B1Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·29 cites·30 claims
- 0998US10138299B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 27, 2018·39 cites·25 claims
- 1098US10072082B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 11, 2018·58 cites·28 claims
- 1198US9856320B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 2, 2018·94 cites·22 claims
- 1298US8119129B2Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseasesJURE-KUNKEL MARIA·Filed 2009·Granted Feb 21, 2012·165 cites·11 claims
- 1398US7288638B2Fully human antibodies against human 4-1BBBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Oct 30, 2007·245 cites·7 claims
- 1497US10584170B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 10, 2020·23 cites·27 claims
- 1597US10577423B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 3, 2020·23 cites·27 claims
- 1697US10316090B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 11, 2019·29 cites·27 claims
- 1797US9605080B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 28, 2017·31 cites·30 claims
- 1897US9212224B2Antibodies that bind PD-L1 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Dec 15, 2015·135 cites·2 claims
- 1997US8685394B2Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseasesJURE-KUNKEL MARIA·Filed 2009·Granted Apr 1, 2014·28 cites·10 claims
- 2096US11608383B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Mar 21, 2023·8 cites·30 claims
- 2196US10100129B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 16, 2018·24 cites·35 claims
- 2296US9320811B2Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseasesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Apr 26, 2016·17 cites·17 claims
- 2396US8716452B2Fully human antibodies against human 4-1BBJURE-KUNKEL MARIA·Filed 2012·Granted May 6, 2014·41 cites·3 claims
- 2496US8475790B2Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseasesJURE-KUNKEL MARIA·Filed 2009·Granted Jul 2, 2013·57 cites·8 claims
- 2596US8137667B2Fully human antibodies against human 4-1BBJURE-KUNKEL MARIA·Filed 2009·Granted Mar 20, 2012·39 cites·3 claims
- 2696US7659384B2Polynucleotides encoding fully human antibodies against human 4-1BBBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Feb 9, 2010·38 cites·20 claims
- 2795US11845805B2Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphomaGENMAB AS·Filed 2021·Granted Dec 19, 2023·5 cites·33 claims
- 2895US10406251B2PD-L1 binding polypeptides for imagingBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 10, 2019·15 cites·35 claims
- 2993US11858995B2Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemiaGENMAB AS·Filed 2021·Granted Jan 2, 2024·4 cites·28 claims
- 3093US9382328B2Fully human antibodies against human 4-1BBBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jul 5, 2016·15 cites·6 claims
- 3192US8449886B2Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseasesJURE-KUNKEL MARIA·Filed 2009·Granted May 28, 2013·11 cites·5 claims
- 3292US2024417471A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 3391US11173219B2PD-L1 binding polypeptides for imagingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 16, 2021·4 cites·21 claims
- 3490US10167343B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 1, 2019·3 cites·34 claims
- 3589US11344639B2PET imaging with PD-L1 binding polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted May 31, 2022·4 cites·13 claims
- 3686US11103579B2Combination of DR5 agonist and anti-PD-1 antagonist and methods of useBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Aug 31, 2021·2 cites·14 claims
- 3786US2024002512A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 3886US2024034793A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 3980US2023051701A1Antibodies against cd73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 4078US2024301078A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2023·Application pending·0 cites
- 4175US2020308282A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 4274US12194110B2PD-L1 binding polypeptides for imagingBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jan 14, 2025·0 cites·15 claims
- 4372US11352440B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 7, 2022·0 cites·18 claims
- 4470US2022098302A1Combination of dr5 agonist and anti-pd-1 antagonist and methods of useBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 4569US2025297028A1Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agentBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 4668US2022389110A1Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agentBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 4768US2024034812A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 4867US2013142805A1Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseasesBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 4966US2019062445A1Fully human antibodies against human 4-1bbBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 5066US2022347324A1Pet imaging with pd-l1 binding polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
Showing the top 50 of 70 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Maria Jure-Kunkel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →